MD2518G2 - Медикаментозный препарат для снижения концентрации холестерина в крови - Google Patents

Медикаментозный препарат для снижения концентрации холестерина в крови Download PDF

Info

Publication number
MD2518G2
MD2518G2 MDA20030284A MD20030284A MD2518G2 MD 2518 G2 MD2518 G2 MD 2518G2 MD A20030284 A MDA20030284 A MD A20030284A MD 20030284 A MD20030284 A MD 20030284A MD 2518 G2 MD2518 G2 MD 2518G2
Authority
MD
Moldova
Prior art keywords
medicamental
reducing
blood
preparation
cholesterol concentration
Prior art date
Application number
MDA20030284A
Other languages
English (en)
Romanian (ro)
Other versions
MD2518F1 (en
Inventor
Элеонора ВАТАМАН
Виктор ПРИСКУ
Вавил КАРАДЖИЯ
Лидия ПАРШАКОВА
Original Assignee
Элеонора ВАТАМАН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Элеонора ВАТАМАН filed Critical Элеонора ВАТАМАН
Priority to MDA20030284A priority Critical patent/MD2518G2/ru
Publication of MD2518F1 publication Critical patent/MD2518F1/xx
Publication of MD2518G2 publication Critical patent/MD2518G2/ru

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к медицине, в частности к медикаментозным препаратам, которые могут быть использованы для снижения липопротеидов низкой плотности (LDL- холестерина), общего холестерина и триглицеридов в сыворотки крови, что ведет к предупреждению и лечению сердечно-сосудистых заболеваний, вызванных атеросклерозом.Сущность изобретения состоит в том, что медикаментозный препарат содержит соевый белок, яблочный пектин в соотношении 7:1, хлористый кальций и воду, при следующем соотношении компонентов, масс. %:
MDA20030284A 2003-12-09 2003-12-09 Медикаментозный препарат для снижения концентрации холестерина в крови MD2518G2 (ru)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20030284A MD2518G2 (ru) 2003-12-09 2003-12-09 Медикаментозный препарат для снижения концентрации холестерина в крови

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20030284A MD2518G2 (ru) 2003-12-09 2003-12-09 Медикаментозный препарат для снижения концентрации холестерина в крови

Publications (2)

Publication Number Publication Date
MD2518F1 MD2518F1 (en) 2004-08-31
MD2518G2 true MD2518G2 (ru) 2005-06-30

Family

ID=32906664

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20030284A MD2518G2 (ru) 2003-12-09 2003-12-09 Медикаментозный препарат для снижения концентрации холестерина в крови

Country Status (1)

Country Link
MD (1) MD2518G2 (ru)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2183964C2 (ru) * 1997-07-30 2002-06-27 Индена С.П.А. Экстракт сои, способ его приготовления и фармацевтическая композиция
AU767245B2 (en) * 1998-11-25 2003-11-06 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2183964C2 (ru) * 1997-07-30 2002-06-27 Индена С.П.А. Экстракт сои, способ его приготовления и фармацевтическая композиция
AU767245B2 (en) * 1998-11-25 2003-11-06 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases

Also Published As

Publication number Publication date
MD2518F1 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
SG152270A1 (en) Immunemodulating oligosaccharides
Safaeian et al. Antioxidant effects of bovine lactoferrin on dexamethasone‐induced hypertension in rat
WO2004103294A3 (en) Methods and compositions for the prevention and treatment of sepsis
EP2322201A3 (en) Compositions and methods for the treatment of immune related diseases
NO20063328L (no) Anvendelse av en fettsyresammensetning som innbefatter minst en av EPA og DHA eller kombinasjoner derav
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
EP1252824A3 (en) Method for improving bone mineralization
ATE373082T1 (de) Pre-adipose zelllinien
AU2728900A (en) Multi-purpose acid compositions
WO2005023185A3 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
WO2005025615A3 (en) FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY
DK1643861T3 (da) Fiber- og kalorierig flydende næringssammensætning til tarmsundhed hos ældre patienter
ATE430572T1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
CY1108138T1 (el) Χρησιμοποιηση λουπινοκονγλουτινης δια την θεραπευτικη αγωγη διαβητου τυπου ιι
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
WO2004058268A3 (de) Verwendung von tetrahydrobiopterinderivaten zur behandlung und ernährung von patienten mit aminosäurestoffwechselstörungen
MD2518F1 (en) Medicamental preparation for reducing the cholesterol concentration in the blood
WO2007097922A3 (en) Receptor-based blood detoxification system
Matsui et al. Antihypertensive effect of salt‐free soy sauce, a new fermented seasoning, in spontaneously hypertensive rats
IL175358A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
US20030133945A1 (en) Natural food supplement
WO2002055694A3 (en) Discriminative nucleic acid analysis using clone sequence signatures
WO2004004649A3 (en) Compositions and methods for the treatment of immune related diseases
JPS6143978A (ja) 野菜ジユ−スの消臭方法
Dargaud et al. Thrombin Generation and Bleeding Phenotype during Personalized Prophylaxis with Recombinant Human FVIII in Previously Treated Patients with Severe Hemophilia A

Legal Events

Date Code Title Description
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
NF4A Restoration of lapsed patent for invention
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees